The aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab-Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first-line therapy in CD33 positive AML. We treated 130 patients, aged <65, with a median age of 52 years.
the setting of relapsed and refractory patients, or to elderly populations considered unfit for an aggressive and conventional approach. [1] [2] [3] Nevertheless, over the last few years many attempts have been made to improve the efficacy, in terms of induction remission rates, of the conventional "3 1 7" schedule, which are usually not higher than 60%-70% in young patients. 2, 3 These innovative approaches included the addition of multidrug resistance (MDR) modulators, the modification of anthracyclines and cytarabine doses, the addition of non-MDR related drugs such as fludarabine and the use, within clinical trials, of targeted agents, such as Gemtuzumab Ozogamicin (GO). 2, [4] [5] [6] [7] This drug, an anti-CD33 antibody conjugated with a cytotoxic antitumor antibiotic (calicheamicin), was first evaluated in the setting of relapsed elderly patients, showing an overall response rate (ORR) of 25%-35%. [5] [6] [7] [8] [9] [10] Subsequently, this drug was tested in younger populations, in five randomized trials, in addition to induction schedules, showing positive results (in four of five trials) in terms of remission rates and safety profile. [11] [12] [13] [14] [15] Unfortunately, the regulatory history of GO has been complicated; in 2010, GO was prematurely withdrawn from the market, but, in 2017, it was resubmitted for review to the FDA and EMA, and, recently, it has been reapproved. [16] [17] [18] [19] We report the final results, with a long follow-up, of a multicenter, The main inclusion criteria were: age range between 18 and 65 years, and previously untreated primary or secondary AML (with bone marrow blasts 20%). All cases were required to express CD33 on blast cells, with a level of expression higher than 20% by flow cytome- /L or more were allowed to initially receive hydroxyurea or a short course of low dose cytarabine to minimize the risk of tumor lysis syndrome. Supporting Figure S1 reports the flow chart of entire therapeutic program.
| Study end points and assessments
The primary endpoint of this prospective multicenter study was to evaluate feasibility, efficacy (ORR) and toxicity of an induction scheme 
| Statistical analysis
Continuous variables were analyzed using descriptive statistical methods (arithmetic mean, standard deviation, median, range, minimum, and maximum). Categorical variables were compared with chi-square test (2-tailed); a value of P 0.05 was considered statistically significant.
Fisher's exact test and t-test were used when appropriate. Survival curves were constructed using the Kaplan-Meier method. OS was Detailed demographics and baseline characteristics are shown in Table 1A .
| Treatment and response
After induction with FLAI-GO, CR rate was 82%; four patients (3%) achieved a PR and 16/130 patients (12%) were primary RES, with an ORR of 85%. There were only four cases (3%) of deaths during induction (DDI) ( Table 1B) . The achievement of CR after FLAI-GO was significantly influenced by cytogenetic molecular risk (Int2-high CR 73% vs low-Int1 CR 90%, P 5 0.02, Fisher's exact test) and diagnosis of secondary AML (secondary leukemia-CR 67% vs de novo AML-CR 90%, 
| Hematological and extra-hematological toxicity
Hematological and extra-hematological toxicity after FLAI-GO are listed in Table 2 .
As expected, all patients experienced grade IV hematological toxicity: median time to neutrophil (>1 3 10 Gastrointestinal toxicity, as reported in Table 2 , was not relevant. 
| Outcome
After a median follow-up of 54 months (range 1-120 months), 67/130 (52%) patients are alive. OS and DFS Kaplan-Meier curves for all patients are shown in Figure 1 . The median OS and DFS were 63 and 61 months, respectively ( Figure 1A,B) . The probability of 1-, 2-, and 5-year OS was 80%, 63%, and 52%, respectively. The probability of 1, 2, and 5-year DFS was 77%, 58%, and 52%, respectively. As reported in Figure 1C ,D, after a long-term follow-up, we did not find significant differences in OS and DFS between patients with favorable cytogenetic molecular risk at diagnosis and other cytogenetic molecular risk groups (OS, Log-rank 0.22; DFS, Log-rank 0.16).
In a Cox univariate analysis, there are the following favorable prognostic factors for OS: achievement of cytological CR after FLAI-GO, age <55 years, molecular remission (MRD-WT1 <70 copies) after FLAI-GO and consolidation with an allogeneic SCT. In a Cox multivariate analysis as reported in Table 3A , age, molecular remission after FLAI-GO, and allogeneic SCT retained statistical significance. The same variables were significantly favorable prognostic factors for DFS as reported in Table 3B . It should be highlighted that PGP overexpression of blast cells and cytogenetic molecular risk at diagnosis did not influence the OS and DFS in this clinical trial.
| D ISC USSION
In the last two decades, few new compounds have been approved for the treatment of AML (Gemtuzumab-Ozogamicin, decitabine, azacitidine, midostaurin), whose therapeutic approach still relies on the administration of conventional chemotherapy ("3 1 7" regimens as induction, followed by cytarabine-based consolidation courses) The rationale for fludarabine and cytarabine combinations is that fludarabine, a fluorinated purine analogue, enhances cytarabine cytotoxicity by increasing cellular concentration of Ara-C 5-triphosphate, thus inhibiting DNA repair. Moreover, fludarabine is toxic against MDR overexpressing blast cells, particularly against PGP-positive leukemic cells both in cell lines and in leukemic blasts. 24, 25, 39 Unfortunately, the MDR overexpression also affects GO activity [40] [41] [42] [43] Recently, Walter et al. documented that the blast cells of patients responding to GO had significantly lower PGP activity and higher CD33 expression than nonresponsive cases. 42, 44 However, in the majority of published trials, patients were not selected according to CD33 expression status and CD33 expression did not appear to have a predictive value for survival. 5, 45 Despite this, van der Velden et al. found that high CD33-antigen loads in peripheral blood limit the efficacy of GO in bone marrow blasts. 46, 47 In clinical daily practice, this suggests that GO might have a higher efficacy in bone marrow blasts if administered after the reduction of CD33 positive blast cells in peripheral blood by standard chemotherapy. 5 For all these reasons, in order to increase the efficacy of a first-line therapy, our FLAI-GO scheme combined both MDR related (anthracyclines) and MDR unrelated drugs (fludarabine), and we adminstered GO on day 6 after the AML debulking with standard chemotherapy.
Interestingly, in our study, 22% of patients had an MDR phenotype with a PGP overexpression on blast cells. However, we found that the MDR PGP overexpression at diagnosis did not have a significant impact on the response to induction therapy, thus supporting the role of FLAI-GO in overcoming this mechanism historically related to chemoresistance.
In terms of efficacy, our data confirmed, in line with MRC AML15 trial, a high ORR rate after induction with FLAI-GO (85%), with a CR of 82%. Notably, 51% (54/106) of patients that obtained a cytological CR after induction, reached complete molecular remission, as assessed by WT1 expression. These findings highlight the ability of the FLAI-GO regimen to induce a good debulking effect and a deep response, supporting the value of WT1 as a marker of MRD, although WT1 is not still worldwide considered a standard tool for MRD assessment. 48, 49 Furthermore, in the present study both univariate and multivariate analysis showed that the achievement of a molecular response after FLAI-GO (WT1 less than 70 copies) significantly improved OS and DFS (Table 3) .
Additionally, in our experience, the cytogenetic molecular risk affects the achievement of CR after FLAI-GO. In particular, Int2-high patients obtained a CR rate of 73% vs low-Int1 patients, in which a CR was reached in 90% of the cases (P 5 0.02, Fisher's exact test). Moreover, as expected, a diagnosis of secondary AML was related to a lower CR rate, when compared to de novo AML (67% vs 90%, P 5 0.003).
In terms of toxicity, after FLAI-GO all patients experienced a grade IV hematological toxicity that required supportive treatment with a median of 11 packed red cell units (range 5-27) and 7 platelet units (range 3-16). Furthermore, documented infections occurred in 38% of the patients, leading to death in only two cases. Hepatic toxicity was extremely low and manageable as reported in Table 2 , confirming a good toxicity profile of GO when it is given at lower doses (3 mg/sqm) as reported in a recent meta-analysis. 10 To confirm the safety profile of FLAI-GO, the DDI rate was very low, accounting for only 3%.
The tolerability coupled with efficacy of FLAI-GO induction approach allowed a high proportion of patients (64%) to proceed to a consolidation and, according to risk stratification, to a SCT procedure (60 patients received an allogeneic SCT, and 23 patients an autologous SCT), with an OS and DFS at 2 and 5 years of 63% and 52%, and of 58% and 52%, respectively. Of note, none of the transplanted patients developed VOD before or after SCT. 50 The high transplantation rate of high and intermediate risk patients of this trial could explain why in this experience the cytogenetic and molecular risk at diagnosis did not significantly impact DFS and OS ( Figure 1C ,D, Table 3 ).
In summary, GO was withdrawn from the U.S. and European mar- Our study confirms these positive results and provides some additional information to better select AML patients, who would most likely benefit from the combination of GO and induction chemotherapy. In our opinion, taking into account all the available data, the best AML The data of this study were presented in part at the EHA 2014
(oral presentation) and published in abstract form (Haematologica 2014).
